The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy
We sought to quantify the additive value of systematic biopsy (SB) using in-bore magnetic resonance (MR)-guided prostate biopsy (IBMRGpB) by retrospectively reviewing the records of 189 patients who underwent IBMRGpB for suspected prostate cancer or as part of the surveillance protocol for previousl...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2023-09, Vol.13 (9), p.1373 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1373 |
| container_title | Journal of personalized medicine |
| container_volume | 13 |
| creator | Lazarovich, Alon Drori, Tomer Zilberman, Dorit E Portnoy, Orith Dotan, Zohar A Rosenzweig, Barak |
| description | We sought to quantify the additive value of systematic biopsy (SB) using in-bore magnetic resonance (MR)-guided prostate biopsy (IBMRGpB) by retrospectively reviewing the records of 189 patients who underwent IBMRGpB for suspected prostate cancer or as part of the surveillance protocol for previously diagnosed prostate cancer. The endpoints included clinically significant and non-clinically significant cancer diagnosis. SB detected clinically significant disease in 67 (35.5%) patients. Five (2.65%) patients whose targeted biopsies indicated benign or non-clinically significant disease had clinically significant disease based on SB. SB from the lobe contralateral to the lesion detected clinically significant disease in 15 (12%) patients. The size of the prostate was larger and the percentage of lesions located in the peripheral zone of the prostate was higher in patients with SB-detected clinically significant disease. The location of the main lesion in the peripheral zone of the prostate was a predictor for clinically significant disease in the multivariate analysis (OR = 8.26, p = 0.04), a finding supported by a subgroup analysis of biopsy-naïve patients (OR = 10.52, p = 0.034). The addition of SB during IBMRGpB increased the diagnosis of clinically significant as well as non-clinically significant prostate cancer. The location of the main lesion in the peripheral zone emerged as a positive predictive factor for clinically significant disease based on SB. These findings may enhance patient-tailored management. |
| doi_str_mv | 10.3390/jpm13091373 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10532510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771803467</galeid><sourcerecordid>A771803467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-951b307d51b7bf994fc06b483c509326cb3d95de9053aa16d647c8b4703bd14b3</originalsourceid><addsrcrecordid>eNptkt9L3TAUgMtwMFGf9g8E9jIY1aT51TyNqzi9oGxMt9eQJqc1lzapTSvc_365KHIdJg8n5HznCyecovhM8CmlCp9txoFQrAiV9ENxWGHJS8YqcbB3_lScpLTBedW8qgQ-LOz9A6CVc-DQX9MvgGKL7rZphsHM3qI7M4y9Dx3yAa1DeR4nQLemC7BL_oYUgwkW0HowXabKq8XvTL-mmGYzAzr3cUzb4-Jja_oEJy_xqPjz4_L-4rq8-Xm1vljdlJaRai4VJw3F0uUgm1Yp1losGlZTy7GilbANdYo7UJhTY4hwgklbN0xi2jjCGnpUfH_2jkszgLMQ5sn0epz8YKatjsbrt5ngH3QXnzTJxooTnA1fXwxTfFwgzXrwyULfmwBxSbqqJSa0ZlJl9Mt_6CYuU8j9ZUooqrjge1RnetA-tDE_bHdSvZKS1JgyITN1-g6Vt4PB2xig9fn-TcG35wKbfzpN0L42SbDeDYPeGwb6D8ovpSk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869395659</pqid></control><display><type>article</type><title>The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Lazarovich, Alon ; Drori, Tomer ; Zilberman, Dorit E ; Portnoy, Orith ; Dotan, Zohar A ; Rosenzweig, Barak</creator><creatorcontrib>Lazarovich, Alon ; Drori, Tomer ; Zilberman, Dorit E ; Portnoy, Orith ; Dotan, Zohar A ; Rosenzweig, Barak</creatorcontrib><description>We sought to quantify the additive value of systematic biopsy (SB) using in-bore magnetic resonance (MR)-guided prostate biopsy (IBMRGpB) by retrospectively reviewing the records of 189 patients who underwent IBMRGpB for suspected prostate cancer or as part of the surveillance protocol for previously diagnosed prostate cancer. The endpoints included clinically significant and non-clinically significant cancer diagnosis. SB detected clinically significant disease in 67 (35.5%) patients. Five (2.65%) patients whose targeted biopsies indicated benign or non-clinically significant disease had clinically significant disease based on SB. SB from the lobe contralateral to the lesion detected clinically significant disease in 15 (12%) patients. The size of the prostate was larger and the percentage of lesions located in the peripheral zone of the prostate was higher in patients with SB-detected clinically significant disease. The location of the main lesion in the peripheral zone of the prostate was a predictor for clinically significant disease in the multivariate analysis (OR = 8.26, p = 0.04), a finding supported by a subgroup analysis of biopsy-naïve patients (OR = 10.52, p = 0.034). The addition of SB during IBMRGpB increased the diagnosis of clinically significant as well as non-clinically significant prostate cancer. The location of the main lesion in the peripheral zone emerged as a positive predictive factor for clinically significant disease based on SB. These findings may enhance patient-tailored management.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm13091373</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biopsy ; Diagnosis ; Health aspects ; Lesions ; Magnetic resonance imaging ; Medical research ; Medicine, Experimental ; Multivariate analysis ; Pathology ; Patients ; Precision medicine ; Prostate ; Prostate cancer ; Surveillance ; Ultrasonic imaging</subject><ispartof>Journal of personalized medicine, 2023-09, Vol.13 (9), p.1373</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-951b307d51b7bf994fc06b483c509326cb3d95de9053aa16d647c8b4703bd14b3</cites><orcidid>0000-0002-2092-4732 ; 0000-0002-7521-5319</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532510/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532510/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Lazarovich, Alon</creatorcontrib><creatorcontrib>Drori, Tomer</creatorcontrib><creatorcontrib>Zilberman, Dorit E</creatorcontrib><creatorcontrib>Portnoy, Orith</creatorcontrib><creatorcontrib>Dotan, Zohar A</creatorcontrib><creatorcontrib>Rosenzweig, Barak</creatorcontrib><title>The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy</title><title>Journal of personalized medicine</title><description>We sought to quantify the additive value of systematic biopsy (SB) using in-bore magnetic resonance (MR)-guided prostate biopsy (IBMRGpB) by retrospectively reviewing the records of 189 patients who underwent IBMRGpB for suspected prostate cancer or as part of the surveillance protocol for previously diagnosed prostate cancer. The endpoints included clinically significant and non-clinically significant cancer diagnosis. SB detected clinically significant disease in 67 (35.5%) patients. Five (2.65%) patients whose targeted biopsies indicated benign or non-clinically significant disease had clinically significant disease based on SB. SB from the lobe contralateral to the lesion detected clinically significant disease in 15 (12%) patients. The size of the prostate was larger and the percentage of lesions located in the peripheral zone of the prostate was higher in patients with SB-detected clinically significant disease. The location of the main lesion in the peripheral zone of the prostate was a predictor for clinically significant disease in the multivariate analysis (OR = 8.26, p = 0.04), a finding supported by a subgroup analysis of biopsy-naïve patients (OR = 10.52, p = 0.034). The addition of SB during IBMRGpB increased the diagnosis of clinically significant as well as non-clinically significant prostate cancer. The location of the main lesion in the peripheral zone emerged as a positive predictive factor for clinically significant disease based on SB. These findings may enhance patient-tailored management.</description><subject>Biopsy</subject><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Lesions</subject><subject>Magnetic resonance imaging</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Multivariate analysis</subject><subject>Pathology</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Surveillance</subject><subject>Ultrasonic imaging</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkt9L3TAUgMtwMFGf9g8E9jIY1aT51TyNqzi9oGxMt9eQJqc1lzapTSvc_365KHIdJg8n5HznCyecovhM8CmlCp9txoFQrAiV9ENxWGHJS8YqcbB3_lScpLTBedW8qgQ-LOz9A6CVc-DQX9MvgGKL7rZphsHM3qI7M4y9Dx3yAa1DeR4nQLemC7BL_oYUgwkW0HowXabKq8XvTL-mmGYzAzr3cUzb4-Jja_oEJy_xqPjz4_L-4rq8-Xm1vljdlJaRai4VJw3F0uUgm1Yp1losGlZTy7GilbANdYo7UJhTY4hwgklbN0xi2jjCGnpUfH_2jkszgLMQ5sn0epz8YKatjsbrt5ngH3QXnzTJxooTnA1fXwxTfFwgzXrwyULfmwBxSbqqJSa0ZlJl9Mt_6CYuU8j9ZUooqrjge1RnetA-tDE_bHdSvZKS1JgyITN1-g6Vt4PB2xig9fn-TcG35wKbfzpN0L42SbDeDYPeGwb6D8ovpSk</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Lazarovich, Alon</creator><creator>Drori, Tomer</creator><creator>Zilberman, Dorit E</creator><creator>Portnoy, Orith</creator><creator>Dotan, Zohar A</creator><creator>Rosenzweig, Barak</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2092-4732</orcidid><orcidid>https://orcid.org/0000-0002-7521-5319</orcidid></search><sort><creationdate>20230901</creationdate><title>The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy</title><author>Lazarovich, Alon ; Drori, Tomer ; Zilberman, Dorit E ; Portnoy, Orith ; Dotan, Zohar A ; Rosenzweig, Barak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-951b307d51b7bf994fc06b483c509326cb3d95de9053aa16d647c8b4703bd14b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biopsy</topic><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Lesions</topic><topic>Magnetic resonance imaging</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Multivariate analysis</topic><topic>Pathology</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Surveillance</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lazarovich, Alon</creatorcontrib><creatorcontrib>Drori, Tomer</creatorcontrib><creatorcontrib>Zilberman, Dorit E</creatorcontrib><creatorcontrib>Portnoy, Orith</creatorcontrib><creatorcontrib>Dotan, Zohar A</creatorcontrib><creatorcontrib>Rosenzweig, Barak</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lazarovich, Alon</au><au>Drori, Tomer</au><au>Zilberman, Dorit E</au><au>Portnoy, Orith</au><au>Dotan, Zohar A</au><au>Rosenzweig, Barak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy</atitle><jtitle>Journal of personalized medicine</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>13</volume><issue>9</issue><spage>1373</spage><pages>1373-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>We sought to quantify the additive value of systematic biopsy (SB) using in-bore magnetic resonance (MR)-guided prostate biopsy (IBMRGpB) by retrospectively reviewing the records of 189 patients who underwent IBMRGpB for suspected prostate cancer or as part of the surveillance protocol for previously diagnosed prostate cancer. The endpoints included clinically significant and non-clinically significant cancer diagnosis. SB detected clinically significant disease in 67 (35.5%) patients. Five (2.65%) patients whose targeted biopsies indicated benign or non-clinically significant disease had clinically significant disease based on SB. SB from the lobe contralateral to the lesion detected clinically significant disease in 15 (12%) patients. The size of the prostate was larger and the percentage of lesions located in the peripheral zone of the prostate was higher in patients with SB-detected clinically significant disease. The location of the main lesion in the peripheral zone of the prostate was a predictor for clinically significant disease in the multivariate analysis (OR = 8.26, p = 0.04), a finding supported by a subgroup analysis of biopsy-naïve patients (OR = 10.52, p = 0.034). The addition of SB during IBMRGpB increased the diagnosis of clinically significant as well as non-clinically significant prostate cancer. The location of the main lesion in the peripheral zone emerged as a positive predictive factor for clinically significant disease based on SB. These findings may enhance patient-tailored management.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/jpm13091373</doi><orcidid>https://orcid.org/0000-0002-2092-4732</orcidid><orcidid>https://orcid.org/0000-0002-7521-5319</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2023-09, Vol.13 (9), p.1373 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10532510 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Biopsy Diagnosis Health aspects Lesions Magnetic resonance imaging Medical research Medicine, Experimental Multivariate analysis Pathology Patients Precision medicine Prostate Prostate cancer Surveillance Ultrasonic imaging |
| title | The Added Value of Systematic Sampling in In-Bore Magnetic Resonance Imaging-Guided Prostate Biopsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T04%3A21%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Added%20Value%20of%20Systematic%20Sampling%20in%20In-Bore%20Magnetic%20Resonance%20Imaging-Guided%20Prostate%20Biopsy&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Lazarovich,%20Alon&rft.date=2023-09-01&rft.volume=13&rft.issue=9&rft.spage=1373&rft.pages=1373-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm13091373&rft_dat=%3Cgale_pubme%3EA771803467%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2869395659&rft_id=info:pmid/&rft_galeid=A771803467&rfr_iscdi=true |